Starling Oncology, Inc. (STLN) Operating income 2020–2025
Starling Oncology, Inc. (STLN) annual operating income history from SEC filings — each fiscal year as reported.
-$36.1MFY2025 · since FY2020: -$8.2M → -$36.1M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -$36.1M | +40.0% |
| FY2024 | -$60.1M | +21.9% |
| FY2023 | -$77.0M | +6.0% |
| FY2022 | -$82.0M | -78.7% |
| FY2021 | -$45.9M | -459.4% |
| FY2020 | -$8.2M | — |
Source: SEC XBRL filings · For reference only · Not investment advice
More STLN financial trends
STLN RevenueSTLN Net incomeSTLN Net marginSTLN Gross profitSTLN Gross marginSTLN Operating marginSTLN Operating cash flowSTLN Free cash flowSTLN Capital expendituresSTLN Return on equitySTLN Stock buybacksSTLN Dividends paidSTLN Total assetsSTLN Total liabilitiesSTLN Shareholders’ equitySTLN overview →